Aeterna Zentaris, Inc. (USA) (AEZS)
A growing global biopharmaceutical company focused on endrocrine therapy and oncology, in drug discovery, development and commercialization.
Recs
Bio Beautiful
Recs
Expecting positive phase 3 results for Cetrorelix sometime this Q
Recs
Short term: This stock is probable to Underperform. The Company provided updated guidance for the 2007 total expected burn in a range of $25-$27 million.
Long term: This will be a hot stock to own. Potential for base case peak annual sales of over $500 million in the United States market alone; lower sales could reach $200 million.
Recs
this company has outstanding leadership along with promising products in various phases. It also MAKES an income and has very good cash balance.
Recs
This is a sure thing, chech this out:
AETERNA ZENTARIS
swap some letters around...
ZANIEST EARN RATE
Recs
undervalued with a strong pipeline.
Recs
Uhhhh............ it will just do bad. :) --A Scientist
Recs
short term recovery
Recs
Small bio-tech with several drugs in pipeline ready for approval.
Recs
Undervalued.
2 Drugs on Market
2 in phase 3
5 in Phase 2
70 million in Cash
Recs
Trading for less than cash + 48% ownership of Atrium Biotech(ATB.TO). Pipeline of drugs is free at this price. Solid mix of partners in US and world including Serono, Solvay, Keryx and Spectrum. Drugs already on the market.
http://www.aeterna.com/pdfdyn/Fact_Sheet_eng.pdf

RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 11 of 11